header logo image

Biotechnology | Wolf Greenfield

August 4th, 2016 9:35 am

G R O U P S T A T S

When it comes to advanced scientific degrees, we field the largest biotechnology group in New England 36 members, over 80% of whom have PhDs or MDs. We aggressively recruit people who develop advanced technology, and who speak the language of inventors and scientists, quickly grasping complex biotechnology matters.

Our clients include both large and emerging biotech companies such as Biogen, Dyax Corporation, and Lantheus Medical Imaging, privately financed startup companies,and prestigious academic and research institutions, including MIT, Dana Farber Cancer Institute, and Harvard Medical School. We understand the different needs of each client and bring practical solutions to the table.

Our expertise is broadand deep, covering areas from antibodies to transgenic technologiesand everything inbetween. We also call on members of our other practice groups includingChemical & Materials Technologies and Pharmaceuticalwhen their specialized expertise will benefit a clients project. In addition, our teams routinely include support from our paralegal group and our International Filing Department to contain costs and deliver value.

Our group's services include: IP strategic planning; patent portfolio development, acquisition, and enforcement; studies on patentability, infringement, and validity; IP audits and due diligence; licensing and technology transfer; defending and challenging patent validity, including post-grant proceedings; and freedom to operate and competitor analyses.

Representative clients:

For older news items, please go to News & Events.

Laura Vogel presents at ACI Conference

Wolf Greenfield and Client Cold Spring Harbor Laboratory Prevail in 4 IPRs

A.J. Tibbetts and Ed Walsh Present at BBA's 16th Annual Intellectual Property Year in Review

Wolf Greenfield Welcomes Counsel Laura Vogel

Wolf Greenfield and Client BTG Reach Favorable Outcome in IPR for CroFab Rattlesnake Antivenom Patent

LMG Life Sciences Recognizes Wolf Greenfield

Wolf Greenfield Welcomes Shareholder Jeffrey Hsi, Expert in Technology Commercialization

Wolf Greenfield Recognized in 2016 "Best Law Firms" Rankings

23 Wolf Greenfield Attorneys Named to 2015 Massachusetts Super Lawyers List

24 Wolf Greenfield Lawyers Named to 2015 Massachusetts Rising Stars List

Oona Johnstone interviewed by ASHG for Featured Chat Fridays

Managing IP Magazine Recognizes Wolf Greenfield

Favorable Outcome for BTG in Snake Antivenom ITC Investigation

Chelsea Loughran talks about CRISPR in Xconomy

20 Wolf Greenfield Lawyers Named to 2014 Massachusetts Rising Stars List

22 Wolf Greenfield Attorneys Named to 2014 Massachusetts Super Lawyers List

Pat Granahan comments on the battle to own CRISPR

Pat Granahan and Chelsea Loughran quoted on CRISPR-Cas in Nature Biotechnology

Patrick Waller interviewed by Radio Entrepreneurs

GenomeWeb quotes Chelsea Loughran on IP landscape surrounding CRISPR-Cas9

Wolf Greenfield Recognized by Managing IP Magazine

Chelsea Loughran quoted in The Scientist on first awarded CRISPR-Cas9 patent

Chelsea Loughran quoted in MIT Tech Review on first awarded patent for engineered CRISPR-Cas9 system

Doug Wolf featured as the Entrepreneur.com expert for the month of March

G R O U P S T A T S

When it comes to advanced scientific degrees, we field the largest biotechnology group in New England 36 members, over 80% of whom have PhDs or MDs. We aggressively recruit people who develop advanced technology, and who speak the language of inventors and scientists, quickly grasping complex biotechnology matters.

Our clients include both large and emerging biotech companies such as Biogen, Dyax Corporation, and Lantheus Medical Imaging, privately financed startup companies,and prestigious academic and research institutions, including MIT, Dana Farber Cancer Institute, and Harvard Medical School. We understand the different needs of each client and bring practical solutions to the table.

Our expertise is broadand deep, covering areas from antibodies to transgenic technologiesand everything inbetween. We also call on members of our other practice groups includingChemical & Materials Technologies and Pharmaceuticalwhen their specialized expertise will benefit a clients project. In addition, our teams routinely include support from our paralegal group and our International Filing Department to contain costs and deliver value.

Our group's services include: IP strategic planning; patent portfolio development, acquisition, and enforcement; studies on patentability, infringement, and validity; IP audits and due diligence; licensing and technology transfer; defending and challenging patent validity, including post-grant proceedings; and freedom to operate and competitor analyses.

Representative clients:

For older news items, please go to News & Events.

Laura Vogel presents at ACI Conference

Wolf Greenfield and Client Cold Spring Harbor Laboratory Prevail in 4 IPRs

A.J. Tibbetts and Ed Walsh Present at BBA's 16th Annual Intellectual Property Year in Review

Wolf Greenfield Welcomes Counsel Laura Vogel

Wolf Greenfield and Client BTG Reach Favorable Outcome in IPR for CroFab Rattlesnake Antivenom Patent

LMG Life Sciences Recognizes Wolf Greenfield

Wolf Greenfield Welcomes Shareholder Jeffrey Hsi, Expert in Technology Commercialization

Wolf Greenfield Recognized in 2016 "Best Law Firms" Rankings

23 Wolf Greenfield Attorneys Named to 2015 Massachusetts Super Lawyers List

24 Wolf Greenfield Lawyers Named to 2015 Massachusetts Rising Stars List

Oona Johnstone interviewed by ASHG for Featured Chat Fridays

Managing IP Magazine Recognizes Wolf Greenfield

Favorable Outcome for BTG in Snake Antivenom ITC Investigation

Chelsea Loughran talks about CRISPR in Xconomy

20 Wolf Greenfield Lawyers Named to 2014 Massachusetts Rising Stars List

22 Wolf Greenfield Attorneys Named to 2014 Massachusetts Super Lawyers List

Pat Granahan comments on the battle to own CRISPR

Pat Granahan and Chelsea Loughran quoted on CRISPR-Cas in Nature Biotechnology

Patrick Waller interviewed by Radio Entrepreneurs

GenomeWeb quotes Chelsea Loughran on IP landscape surrounding CRISPR-Cas9

Wolf Greenfield Recognized by Managing IP Magazine

Chelsea Loughran quoted in The Scientist on first awarded CRISPR-Cas9 patent

Chelsea Loughran quoted in MIT Tech Review on first awarded patent for engineered CRISPR-Cas9 system

Doug Wolf featured as the Entrepreneur.com expert for the month of March

Some areas of expertise

Read more:
Biotechnology | Wolf Greenfield

Related Post

Comments are closed.


2024 © StemCell Therapy is proudly powered by WordPress
Entries (RSS) Comments (RSS) | Violinesth by Patrick